Amneal Launches Generic Lanreotide After FDA Approval, Targeting $983M Market
AMRX sits 97% above its 52-week low of $9.49 on elevated volume (2.6× avg).
Summary
Amneal received FDA approval for its lanreotide injection, a generic version of Ipsen's Somatuline Depot, and is launching immediately. The product targets a U.S. market with $983 million in annual sales, and Amneal secured Competitive Generic Therapy designation, which can provide 180 days of exclusivity. This is a material addition to the Affordable Medicines segment and follows the company's raised 2026 guidance and recent Kashiv BioSciences acquisition. The launch adds a high-value complex injectable to the portfolio, with in-house manufacturing supporting supply. Watch for initial prescription uptake and any commentary on the next earnings call regarding revenue contribution.
At the time of this announcement, AMRX was trading at $18.71 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $6B. The 52-week trading range was $9.49 to $19.26. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.